Aescuvest’s Investment Committee: The League of Extraordinary Ladies and Gentlemen
Today, we would like to introduce you to aescuvest’s Investment Committee, the foundation of our work and the icing on the cake at the same time.
We are thrilled to have assembled a cast of ten professionals hailing from six different countries that carefully screen and select the companies and projects that are pitching for a free slot on the aescuvest platform. Each member of the committee brings a different expertise and thus perspective to the table, be it medicine, finance, asset management, legal affairs, digital health, you name it. We want the companies that we are hosting to be successful which is why we put so much emphasis on quality control. Thus, we ensure that on the one hand innovative companies and their products enter the market and investors on the other hand have access to those innovative companies and benefit from their growth. Also, we welcome the fact that our committee represents various age groups and also a strong female view (which is often neglected in finance).
While the committee physically gathers in Frankfurt/Main on a quarterly basis, its members assess the applications individually and independently online. They submit their assessment and cast their votes via a score card which means every start-up is awarded points for categories such as “level of innovation”, “business model”, “market size”, last not least “team”. If the accumulated score of all members does not reach a certain score or if only one member awards the team a particularly low score, it’s a showstopper. However, if the applicants are able to convince the committee and tick all boxes, the startup will enter the next phase.
So, meet the team then! In alphabetical order, the committee’s members are:
He is the rare mix of academics and practical operator. One who doesn’t talk, but tackles. One whose experiences benefits all. Entrepreneur and manager by conviction. He knows the way to show others how to succeed anyway and how they learn to fight for their idea: “Most people did not know how close they had come to their goal just as they were giving up.” Such guys give courage! This is the reason why aescuvest is lucky to have him on board. Southern temperament and irrepressible optimism are his trademarks.
Prof. Dr. Clemens Bulitta is the perfectionist: physician, surgeon and scientist as well as teacher and top manager in the international healthcare sector. It is a truly impressive combination of expertise in vari-ous fields of medical engineering that he has acquired at some of the most renowned universities of the world. Sound in theory, Prof. Dr. Bulitta has a decade of experience working for an international-ly leading med-tech corporation and maintains an excellent network in the business sector.
Dr. Mynia Deeg is a unique specialist with a 360° view of digital health. She knows how to manage interfaces between future-oriented concepts and technical needs. Dr. Deeg analyses the main obstacles between ingenious inventions and commercial success. Her realistic assessment allows her to evaluate demand and prospects for every start-up idea in the digital health world.
Independent guardian of standards and senior supervisor. Over 30 years of far-reaching experience in leading financial centers; positions in Europe, Asia and U.S. – thus broad international expertise in Investment Banking, Private Banking, Asset Management, Hedge Funds combined with in-depth knowledge of emerging markets. Franz Friedl is a keen strategic thinker with the ability to ensure impact and implementation of appropriate policies. With regards to the partnership between aescuvest and EIT Health, he will monitor and support also operational processes.
Independent guardian of standards and senior supervisor to secure all business processes. Over 30 years of far-reaching experience in leading financial centers. Senior positions in Europe, Asia and U.S. Broad international expertise in Investment Banking, Private Banking, Asset Management, Hedge Funds. In-depth knowledge of Emerging Markets, establishment of new companies, special structures and operations as well as restructuring and re-alignment. Strategic thinking and implementation of ensuing policies. M&A experience through acquisitions as wells as disposals of business units.
German qualified lawyer and bachelor professional of Investment has been working for several years in investment banking as well as in asset management and financial services business. Specialized in the fields of Capital Market Laws, Supervisory Laws and Risk Management. He has profound knowledge of corporate governance and compliance standards, is highly experienced in the development of financial products and very focused on details.
Prof. Dr. Thomas Schlegel is a lawyer and lecturer on medical law in the field of health and pharmaceutical economics. He is an expert with an in-depth knowledge of legal pitfalls and market entry barriers. A specialist in optimising business models for the healthcare sectors, Prof. Dr. Schlegel ensures that potential reimbursement of product is secured, property rights are safeguarded, limits assessed and the opportunities of legal permissibility are recognised. He is a constructive analyst when it comes to rating the chances of success in the field of medical services and pharmaceuticals.
A multi-disciplinary specialist connecting expertise in Biochemistry, Immunology, Bioengineering and Cell Theraphies. He has been awarded scholarships and is the winner of several renowned international awards. As a serial entrepreneur he is creating, supporting and funding a new generation of biotech start-ups being deeply rooted in the technology and finance ecosystems of both Asia and Europe. Aescuvest is honoured to have him as part of the Committee.
He is bringing more than 20 years of expertise in innovative healthcare and financial service businesses to the table. From a renowned strategy consultancy his career led him up to the director level at the world’s largest insurance groups, where he gained valuable experience in various European countries. As currently General Partner of the Medical Valley Venture Company he enables active support and market access to technology start-ups.